Nicole Junkermann, founder of NJF Capital, presents Deep Genomics, a healthtech company that is using artificial intelligence to build a new universe of life-saving genetic therapies.
The future of drug development will rely on artificial intelligence because biology is too complex for humans alone to fully understand.
Canadian artificial intelligence therapeutics company Deep Genomics is pioneering the use of AI to revolutionise drug development.
In 2019, Deep Genomics announced that it had identified a potential drug candidate for Wilson disease, a rare and potentially life-threatening genetic disorder.
Clinical trials for the new drug are planned for 2021.
In January 2020, Deep Genomics raised $40 million in Series B financing.
70% of Deep Genome research projects have led to therapeutic leads and programs have been taken from target discovery to drug candidate in under twelve months.
The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using their biologically accurate artificial intelligence technology.
Deep Genomics uses AI to systematically discover new therapies with a far higher success rate than traditional pharma methods.